Funding Wizard

Invasive surgical procedures offer the opportunity for unique intracranial interventions such as the ability to record and stimulate intracranially within precisely localized brain structures in humans. Human studies using invasive technology are often constrained by a limited number of patients and resources available to implement complex experimental protocols and need to be aggregated in a manner that addresses research questions with appropriate statistical power. Therefore, this RFA seeks applications to assemble diverse, integrated, multi-disciplinary teams that cross boundaries of interdisciplinary collaboration to overcome these fundamental barriers and to investigate high-impact questions in human neuroscience. The research should be offered as exploratory research and planning activities to establish feasibility, proof-of-principle and early-stage development that, if successful, would support, enable, and/or lay the groundwork for a potential, subsequent Research Opportunities Using Invasive Neural Recording and Stimulating Technologies in the Human Brain, as described in the companion FOA (RFA-NS-22-041). Projects should maximize opportunities to conduct innovative in vivo neuroscience research made available by direct access to the brain from invasive surgical procedures. Projects should employ approaches guided by specified theoretical constructs and by quantitative, mechanistic models where appropriate. Awardees will join a consortium working group, coordinated by the NIH, to identify consensus standards of practice, including neuroethical considerations, to collect and provide data for ancillary studies, and to aggregate and standardize data for dissemination among the wider scientific community.

The purpose of the The Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative Fellows (F32) program is to enhance the research training of promising postdoctorates, early in their postdoctoral training period, who have the potential to become productive investigators in research areas that will advance the goals of the BRAIN Initiative. Applications are encouraged in any research area that is aligned with the BRAIN Initiative, including neuroethics. Applicants are expected to propose research training in an area that clearly complements their predoctoral research. Formal training in analytical tools appropriate for the proposed research is expected to be an integral component of the research training plan. In order to maximize the training potential of the F32 award, this program encourages applications from individuals who have not yet completed their terminal doctoral degree and who expect to do so within 12 months of the application due date. On the application due date, candidates may not have completed more than 12 months of postdoctoral training.

The U.S. Department of State, Bureau of Democracy, Human Rights, and Labor (DRL) announces an open competition for organizations interested in submitting applications for projects that strengthen opposition governance actors’ ability to design policies that are responsive to the needs of local communities, promote democratic norms, and protect fundamental freedoms.

As part of the ADVANCE: Advancing Prevention Research for Health Equity program, the NIH Office of Disease Prevention (ODP) within the Office of the Director Division of Program Coordination, Planning, and Strategic Initiatives (DPCPSI) is soliciting revision applications (formerly called "competitive revisions") to active R01 grants to support studies that develop and evaluate menthol cigarette smoking cessation and prevention interventions for populations that experience health disparities.

The SCIRP CTA supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of SCI. Applications should articulate both the short- and long-term impact of the proposed research on individuals with SCI and/or their care partners. The proposed intervention(s) to be tested should offer significant potential impact for individuals affected by SCI within the context of one or more of the FY23 SCIRP Focus Areas.Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first in human, phase 0), to demonstrate feasibility or inform the design of more advanced trials, through large-scale trials to determine efficacy in relevant populations. Alternative trial designs to traditional randomized clinical trials are allowed but should be appropriate to the objective of the trial. Utilization of decentralized clinical trial strategies that leverage virtual elements/tools for participant enrollment, communication, and data collection is especially encouraged.The proposed research must be relevant to active-duty Service Members, Veterans, military beneficiaries, and/or the American public. To help elucidate the realities of treating and managing SCIs while deployed, a resource document is now available on the CDMRP website that outlines Spinal Cord Injury Management Within the Military Health System (MHS). Applicants are encouraged to read and consider this document before preparing their applications. The resource can be accessed at https://cdmrp.health.mil/scirp/pdfs/ Beginner's%20Guide%20to%20Military%20Health%20System.pdf.Employing community collaborations to optimize research impact is required. Research funded by the FY23 SCIRP CTA should be responsive to the needs of people with SCI, their families, and/or their care partners. Research teams are therefore required to establish and utilize effective and equitable collaborations and partnerships with community members to maximize the translational and impact potential of the proposed research. Applications to the FY23 SCIRP CTA are expected to name at least two community partners (e.g., SCI Lived Experience Consultants, representatives of community-based organizations) who will provide advice and consultation throughout the planning and implementation of the research project (see Attachment 4, Collaborative Research Plan).Collaborative research approaches, such as community-based participatory research, participatory action research, and integrated knowledge transition, create partnerships between scientific researchers and community members to create knowledge useable by both sets of stakeholders. Recognizing the strengths of each partner, scientific researchers and community members collaborate and contribute equitably on all aspects of the project, which may include needs assessment, planning, research intervention design, implementation, evaluation, and dissemination. Collaborative research approaches feature shared responsibility and ownership for the research project to ensure non-tokenistic involvement of community members within the research team. Research results are jointly interpreted, disseminated, fed back to affected communities, and may be translated into interventions or policy. These methods are critically important for community-level interventions and can also have important impacts on translational research and prototype development to identify and augment the potential impact of a research program on people living with SCI, their families, and/or their care partners.Collaborative relationships with the lived experience community are often established through integrating community members into research teams as co-researchers, advisors, and/or consultants. Some examples for implementing collaborative research approaches include:• Lived Experience Consultation: The research team includes at least one project advisor with lived SCI experience who will provide advice and consultation throughout the planning and implementation of the research project. Lived Experience Consultants may include individuals with SCI, their family members, and/or their care partners.• Partnership with a Community-Based Organization: The research team establishes partnerships with at least one community-based organization that provides advice and consultation throughout the planning and implementation of the research project. Community-based organizations may include advocacy groups, service providers, policymakers, or other formal organizational stakeholders.• Community Advisory Board Utilization: A community advisory board is composed of multiple community stakeholders and can take many forms, from a board of Lived Experience Consultants to a coalition of community-based organizations or any combination thereof. As with Lived Experience Consultants and organizational partners, the community advisory board provides advice and consultation throughout planning and implementation of the research project.

The SCIRP TRA is intended to support translational research that will accelerate the movement of promising ideas in SCI research into clinical applications. Although not all-inclusive, some examples include demonstration studies of pharmaceuticals and medical devices in preclinical systems and/or clinical research on therapeutics, devices, or practice using human tissues or resources.The ultimate goal of translational research is to move an observation forward into clinical application and accelerate the clinical introduction of health care products, technologies, or practice guidelines. Observations that drive a research idea may be derived from a laboratory discovery, population-based studies, or a clinician’s first-hand knowledge of patients and anecdotal data. However, applicants should not view translational research as a one-way continuum from bench to bedside. The research plan is encouraged to involve a reciprocal flow of ideas and information between basic and clinical science.Applicants need to clearly articulate three points along the translational research spectrum:• Where the field is now;• Where the field will be after the successful completion of the proposed research project; and• What the next step will be after completion of the proposed project.Applications must include preliminary and/or published data that are relevant to SCI and supports the proposed research project.Applications to the FY23 SCIRP TRA may include preclinical animal studies (except where otherwise specified) and/or clinical research involving human subjects and human anatomical substances. Proposal of animal studies is not a required element of this mechanism though applications including animal studies must include a clear justification for the animal model chosen including relevance to human SCI. The FY23 SCIRP TRA may also support ancillary studies that are associated with an ongoing or completed clinical trial and projects that optimize the design of future clinical trials.The FY23 SCIRP TRA also allows funding for a pilot clinical trial as PART of the funded research project where limited clinical testing of a novel intervention or device is necessary to inform the next step in the continuum of translational research. Such pilot clinical trial studies should be small, make up only a portion of the proposed Statement of Work (SOW), and be utilized to establish feasibility of a potential approach or to aid in device or intervention refinement. Alternative trial designs to traditional randomized clinical trials are allowed but should be appropriate to the objective of the trial. If a pilot clinical trial is proposed, utilization of decentralized clinical trial strategies that leverage virtual elements/tools for participant enrollment, communication, and data collection is especially encouraged. Applications that include a pilot clinical trial as part of the proposed research will have additional submission requirements and review criteria. Applications that consist entirely of a clinical trial or multiple pilot clinical trials may be administratively withdrawn.

Through this funding opportunity announcement, the National Cancer Institute (NCI) intends to focus on the impacts of climate change across the cancer control continuum (R01 Clinical Trial Optional)

This program element does not have a proposal due date. Step-1 proposals may be submitted at any time, pending certain eligibility timing issues related to resubmissions and duplicate proposal avoidance, see the program element text and appropriate overview appendix (e.g., B.1 or C.1). The date shown of 3/29/2024 is the last day that proposals may be submitted subject to the ROSES-23 rules and the current Guidebook for Proposers. The ROSES-24 version of this program element is planned to overlap with this ROSES-23 version by a few weeks, allowing continuous submission of proposals across ROSES years. Step-1 proposals will receive an encouraged or discouraged review at which time they may prepare and submit a Step-2 proposal in accordance with the schedule outlined in the decision communication. Proposers must retrieve the instructions document (zip file) associated with the application package for this opportunity as there is at least one required form that must be attached to the submitted proposal package. The National Aeronautics and Space Administration (NASA) Science Mission Directorate (SMD) released its annual omnibus Research Announcement (NRA), Research Opportunities in Space and Earth Sciences (ROSES) – 2023 (OMB Approval Number 2700-0092, CFDA Number 43.001) on February 14, 2023. In this case "omnibus" means that this NRA has many individual program elements, each with its own due dates and topics. All together these cover the wide range of basic and applied supporting research and technology in space and Earth sciences supported by SMD. Awards will be made as grants, cooperative agreements, contracts, and inter- or intra-agency transfers, depending on the nature of the work proposed, the proposing organization, and/or program requirements. However, most extramural research awards deriving from ROSES will be grants, and many program elements of ROSES specifically exclude contracts, because contracts would not be appropriate for the nature of the work solicited. The typical period of performance for an award is three years, but some programs may allow up to five years and others specify shorter periods. In most cases, organizations of every type, Government and private, for profit and not-for-profit, domestic and foreign (with some caveats), may submit proposals without restriction on teaming arrangements. Tables listing the program elements and due dates (Tables 2 and 3), a table that provides a very top level summary of proposal contents (Table 1), and the full text of the ROSES-2023 "Summary of Solicitation", may all be found NSPIRES at http://solicitation.nasaprs.com/ROSES2023. This synopsis is associated with one of the individual program elements within ROSES, but this is a generic summary that is posted for all ROSES elements. For specific information on this particular program element download and read the PDF of the text of this program element by going to Tables 2 or 3 of this NRA at http://solicitation.nasaprs.com/ROSES2023table2 and http://solicitation.nasaprs.com/ROSES2023table3, respectively, click the title of the program element of interest, a hypertext link will take you to a page for that particular program element. On that page, on the right side under "Announcement Documents" the link on the bottom will be to the PDF of the text of the call for proposals. For example, if one were interested in The Lunar Data Analysis Program (NNH23ZDA001N-LDAP) one would follow the link to the NSPIRES page for that program element and then to read the text of the call one would click on “C.8 Lunar Data Analysis (.pdf)” to download the text of the call. If one wanted to set it into the context of the goals, objectives and know the default rules for all elements within Appendix C, the planetary science division, one might download and read “C.1 Planetary Science Research Program Overview (.pdf)” from that same page. While the letters and numbers are different for each element within ROSES (A.12, B.7, etc.) the basic configuration is always the same, e.g., the letter indicates the Science Division (A is Earth Science, B is Heliophysics etc.) and whatever the letter, #1 is always the division overview. Frequently asked questions for ROSES are posted at http://science.nasa.gov/researchers/sara/faqs. Questions concerning general ROSES-2023 policies and procedures may be directed to Max Bernstein, Lead for Research, Science Mission Directorate, at sara@nasa.gov, but technical questions concerning specific program elements should be directed to the point(s) of contact for that particular element, who may be found either at the end of the individual program element in the summary table of key information or on the web list of topics and points of contact at: http://science.nasa.gov/researchers/sara/program-officers-list. Not all program elements are known at the time of the release of ROSES. To be informed of new program elements or amendments to this NRA, proposers may subscribe to: (1) The SMD mailing lists (by logging in at http://nspires.nasaprs.com and checking the appropriate boxes under "Account Management" and "Email Subscriptions"), (2) The ROSES-2023 blog feed for amendments, clarifications, and corrections to at http://science.nasa.gov/researchers/sara/grant-solicitations/ROSES-2023, and (3) The ROSES-2023 due date Google calendars (one for each science division). Instructions are at https://science.nasa.gov/researchers/sara/library-and-useful-links (link from the words due date calendar).

The SCIRP CTRA is intended to support high-impact and/or new/emerging clinical research that may not be ready for a larger-scale clinical trial and for which feasibility/pilot studies are necessary. Projects should demonstrate potential to impact the standard of care, both immediate and long term, or contribute to evidence-based guidelines for the evaluation and care of military Service Members, Veterans, and other individuals living with SCI.• One goal of the FY23 SCIRP CTRA is to translate current and emerging techniques and interventions into the clinical space to de-risk and inform the design of more advanced trials.• Another goal is to identify the most effective diagnosis, treatment, and rehabilitation options available to support critical decision-making for patients, clinicians, care partners, and policymakers.The application should clearly articulate the scientific and strategic steps and/or preparations the research team will take during AND after the project’s period of performance to advance the research to the next stage of clinical development/implementation.The proposed studies may be interventional or observational and may involve some retrospective data analysis. Note that purely retrospective or database-related research will not be supported under this funding opportunity, some element of prospective human enrollment should be included in the project. Small/pilot clinical trials with human subjects are allowable. Alternative trial designs to traditional randomized clinical trials are allowed but should be appropriate to the objective of the trial. If a clinical trial is proposed, utilization of decentralized clinical trial strategies that leverage virtual elements/tools for participant enrollment, communication, and data collection is especially encouraged.The FY23 SCIRP CTRA differs from the FY23 SCIRP Clinical Trial Award (Funding Opportunity Number HT9425-23-SCIRP-CTA) in that the CTRA allows for the execution of both clinical research projects and clinical trials, whereas the Clinical Trial Award is restricted to the execution of clinical trials only.The FY23 CTRA differs from the FY23 SCIRP Translational Research Award (Funding Opportunity Number HT9425-23-SCIRP-TRA) in that the study proposed within an application to the FY23 SCIRP CTRA may consist entirely of a clinical trial. In contrast, if a clinical trial is proposed within a Translational Research Award application, it must make up only a portion of the project’s Statement of Work.Applications to the FY23 SCIRP CTRA mechanism must support prospective clinical research or clinical trials and may not be used for animal research. Investigators seeking support to conduct studies involving animal research should consider applying to the FY23 SCIRP Translational Research Award mechanism (Funding Opportunity Number HT9425-23-SCIRP-TRA) or FY23 SCIRP Investigator-Initiated Research Award mechanism (Funding Opportunity Number HT9425-23-SCIRP-IIRA).

The Bureau of Counterterrorism (CT) of the U.S. Department of State announces an open competition for organizations to submit applications to utilize existing Somalia Police Force (SPF) MVCP cadre to create three to four additional SPF mobile vehicle checkpoint (MVCP) teams to expand operations throughout Mogadishu intended to disrupt terrorists’ ability to use VBIEDs and to move lethal aid.